Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. - Wikidata - awgldk - TriplyDB

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

http://www.wikidata.org/entity/Q34633758

about

Radioisotopes for metastatic bone pain Applications of 211At and 223Ra in targeted alpha-particle radiotherapy From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide Therapy Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 Targeting bone physiology for the treatment of metastatic prostate cancer Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Novel non-AR therapeutic targets in castrate resistant prostate cancer The elements of life and medicines Radium-223 dichloride in clinical practice: a review.Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.WITHDRAWN: Radioisotopes for metastatic bone pain.Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease A high-throughput screen for alpha particle radiation protectants.Recent advances in bone-targeted therapies of metastatic prostate cancer Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.Bone-targeting agents in prostate cancer.Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.Emerging treatment options for patients with castration-resistant prostate cancer.Evolving role of bone biomarkers in castration-resistant prostate cancer.Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases.Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.Systemic targeted alpha radiotherapy for cancer.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Targeted alpha anticancer therapies: update and future prospects Alpha particles induce apoptosis through the sphingomyelin pathway.Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.

P2860

Q24235589-DE4CEB96-5B8A-45AF-A4A3-C3D7ABBA7CCE Q24610016-5B5005A6-A477-44B9-8BE4-B9F229121D1A Q26740064-2E982F93-764E-433E-B3C0-B9B160674034 Q26752785-36B7F34B-720B-4947-BEE0-AF547C64779A Q26768478-110F3FC2-BE10-4BFB-9F81-5B324C31971D Q26851608-9879E740-62FE-460E-B95F-3F3CEB462A96 Q26861575-F7FED1DB-9FE2-4ED8-97B6-53136549ECB8 Q26863249-1D652174-E075-4BEB-AA75-B7A4B6FFF39A Q27010542-30ED9D91-A2F7-4E05-BD12-4BAA82848151 Q27022567-2F45AEA7-4B2A-4398-8E30-3CB9E2F94BAD Q28077633-7C8E2845-DD7E-4F5F-A681-3AA7A1F4A94C Q28079918-9AB7E9ED-FE7F-4170-9B6A-1AFE4BBB5F4D Q28383663-33F1EE83-D17B-4823-8F93-B31FD9EDF848 Q28649323-456B5198-81B2-4034-8124-1CAFAE12A2F5 Q30251496-0FCAAD81-4CD1-4AE9-B001-6E5645B55E71 Q30521133-314E37CC-D7F5-4AF5-88D5-DE67A93F25DF Q33405335-8622A7B9-C7BB-4B38-9918-9AE35026AB41 Q33408024-276BC562-2CE8-4DCC-9AC4-1492F9FAD1D6 Q33419685-2BE89396-FE14-4415-80EC-82AE9CCA83A3 Q33437726-1365ADE2-0C9F-4967-AA27-D7AD8D3C921B Q33440341-C952F71A-FF41-4971-B7BC-7E6EDFE951AE Q33441176-2FDE00F4-7B39-42F0-9BB3-345B2CFA89FE Q33628466-AB6AEF25-6C54-433C-96F5-C067FFB0A851 Q33640606-CF4E4108-A93A-4568-B301-71820990E51C Q33703763-F082D2E4-51E9-4840-A696-92B94AE8911F Q33789188-91C2CC0F-D59B-45E2-BCF0-E5A2A5129CA7 Q33864723-2855CE7B-3CEE-44D0-8BCC-DFC9DFF1E1D0 Q33942600-2DBE082A-8FF3-428C-803D-F1D045CDCE82 Q33958519-B8A38AC0-042E-4955-97AF-68F2193E9D29 Q34023877-A5E4A9DB-5EB2-46D9-BE3C-9DD71F003B30 Q34243421-26C00978-848A-434B-B88D-384FBF2F5C26 Q34323756-355A013D-AFD8-4568-9FC0-8846348F7F82 Q34348226-5CF7F55D-C881-4352-B724-52D4FA60C854 Q34374096-5A5EC268-851A-4700-8B87-545C3294CD15 Q34377594-5F33F5B8-7749-42F8-ADD1-CB7E778A24E4 Q34387852-2F67EBB4-34FC-46E3-BDBA-1AF2A64B3A7F Q34511439-E80E709B-21CB-4492-ADEA-2A735BFC8555 Q35258065-7DD7067B-CB06-4A54-BE4C-143913E6B90D Q35623683-97B46BEC-7260-4057-BAB1-FAC2F3180169 Q35650472-22E209A4-D898-42D2-B3A2-249E31FFF8DD

P2860

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

http://www.wikidata.org/entity/Q34633758

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@ast

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@en

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@nl

type

label

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@ast

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@en

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@nl

prefLabel

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@ast

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@en

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@nl

P1433

Q34633758-43532ABE-5CBF-4BA2-882B-158ADD75E047

P1476

Q34633758-D5A51172-BC0E-4317-A9FA-62D24EAB6D7C

P2093

Q34633758-0B437F14-539B-4EE8-BA2B-BA5F03CB246E

Q34633758-145D0D7C-D7DE-41E2-99BA-F79E250CC36D

Q34633758-1B23C97B-9F54-44B5-80CF-F14626C4EB5C

Q34633758-287DE78F-B5E9-4506-B5C8-752BBDF9949B

Q34633758-29729A8F-FACA-4D5A-9334-5B1EEB80A8DA

Q34633758-3472EE10-F608-49AD-A5BF-068F985A314C

Q34633758-3A0BE57C-9AFF-4B32-9CB3-636386A8401F

Q34633758-40D6CE3F-AB30-4D47-A533-39AD9FDD1805

Q34633758-45CB2555-A107-4107-9BA4-9EE31900667D

Q34633758-4C49F8B0-1A9D-48DC-9057-74B9ECD769CF

P304

Q34633758-132A1B73-333A-44AD-BC02-08B68BD93197

P31

Q34633758-457EDAA1-22E8-4889-B069-27E3C1AD5ED5

P356

Q34633758-2DFA1C14-8F06-43FA-AE98-A3D255CDB2B0

P433

Q34633758-59932DBB-20F7-4EF2-945A-DFA3BA9323FC

P478

Q34633758-E1CBB0DB-A075-43EA-928B-3AB1548627E0

P50

Q34633758-33CFADF4-06C9-4E3E-9231-F0456DCD3EF7

P577

Q34633758-2B578A6B-C7C6-4043-9B7F-9FE2B490130B

P5875

Q34633758-1F025A83-71B6-4595-816F-62352834BA3C

P698

Q34633758-F2FCE13E-2E2C-462A-AE4D-8A1541A8F47D

P921

Q34633758-C4447673-EF48-4BD9-98DB-4121DB353290

Q34633758-F86BBDEE-B497-460B-B168-40F9A2B4E093

P356

S1470-2045(07)70147-X

P1433

The Lancet Oncology

P1476

Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.

@en

P2093

Bjørg Bolstad

http://www.w3.org/2001/XMLSchema#string

Bo Lennernäs

http://www.w3.org/2001/XMLSchema#string

Christopher Parker

http://www.w3.org/2001/XMLSchema#string

Christopher Tyrrell

http://www.w3.org/2001/XMLSchema#string

Dag C Johannessen

http://www.w3.org/2001/XMLSchema#string

Jan Tennvall

http://www.w3.org/2001/XMLSchema#string

Jeffrey Yachnin

http://www.w3.org/2001/XMLSchema#string

Johan Harmenberg

http://www.w3.org/2001/XMLSchema#string

Katharine Pigott

http://www.w3.org/2001/XMLSchema#string

Lars Franzén

http://www.w3.org/2001/XMLSchema#string

P304

587-594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(07)70147-X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Øyvind Sverre Bruland

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6291331

http://www.w3.org/2001/XMLSchema#string

P698

17544845

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial